STOCK TITAN
  1. Home
  2. News
  3. VERV

Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Verve Therapeutics (VERV) to Present at J.P. Morgan Healthcare Conference on January 8, 2024
Positive
  • None.
Negative
  • None.

BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco.

A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.

About Verve Therapeutics 
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as pharmacologic targets for lowering low-density lipoprotein cholesterol (“LDL-C”), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com

 


Verve Therapeutics' CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 at 4:30 p.m. PT in San Francisco.

The live webcast will be available in the investor section of the company's website at www.vervetx.com.

The webcast will be archived for 30 days following the presentation on Verve Therapeutics' website.
Stock VERV logo
Verve Therapeutics Inc

NASDAQ:VERV

VERV Rankings

#2949 Ranked by Market Cap
#5259 Ranked by Stock Gains
N/A Ranked by Dividends

VERV Latest News

Apr 2, 2024
Verve Therapeutics Announces Updates on its PCSK9 Program
Mar 28, 2024
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2024
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb 27, 2024
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 1, 2024
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

VERV Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About VERV

verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.